Patent Expiries of Major Blockbusters to Drive Biosimilar Market
In US alone drugs worth US$ 67 Billion will lose patent protection by 2020. These patent expiries lined up until 2020 are proving to be the major driver for the biosimilar market. Most of these biologics belong to the category of mAbs and as evident from the pipeline, biosimilar manufacturers are eagerly waiting for them to lose their patents, so that biosimilars can cash in quickly.
View full press release